Carlsmed — Third Quarter 2026 Earnings Summary

Carlsmed reported third-quarter 2026 revenue of $21.6 million, marking a 65% increase compared to the same period in 2025. The company raised its full-year 2026 revenue guidance to a range of $78 million to $80 million, reflecting over 56% growth at the midpoint versus 2025. During the quarter, gross profit reached $16.7 million with a gross margin of 77.3%, while operating expenses increased to $29.4 million due to executive transition costs and legal settlements. Additionally, Carlsmed secured new inpatient CMS reimbursement for its aprevo lumbar spine fusion procedure and launched a new bilateral posterior system.